Financial Performance - The company reported total revenue of 172 million yuan for the first half of 2025 [1] - The net profit attributable to shareholders was -35.73 million yuan [1] - The net cash inflow from operating activities was -38.96 million yuan, a decrease of 757,900 yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 39.34%, an increase of 0.34 percentage points from the previous quarter and 0.73 percentage points from the same period last year [3] - The latest gross profit margin is 17.88%, a decrease of 10.15 percentage points from the previous quarter and 27.19 percentage points from the same period last year [3] - The latest return on equity (ROE) is -4.87%, a decrease of 0.32 percentage points from the same period last year [3] Earnings and Shareholder Information - The diluted earnings per share are -0.05 yuan [3] - The latest total asset turnover ratio is 0.14 times [3] - The latest inventory turnover ratio is 3.68 times [3] - The number of shareholders is 19,000, with the top ten shareholders holding 451 million shares, accounting for 62.54% of the total share capital [3]
灵康药业(603669.SH):2025年中报净利润为-3573.37万元